Liberty Global Ltd Class C vs Relay Therapeutics Inc. Common Stock — how do they compare? Liberty Global Ltd Class C trades at $8.44 (market cap $3.06B), while Relay Therapeutics Inc. Common Stock trades at $18.28 (market cap $3.82B). The key difference: Relay Therapeutics Inc. Common Stock is the larger of the two by market cap, and Relay Therapeutics Inc. Common Stock is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liberty Global Ltd Class C for 21 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| LBTYK | RLAY | |
|---|---|---|
Market Cap | $3.06B | $3.82B |
Volume | 2,508,956 | 4,332,079 |
Sector | Media | Health |
52-Week High | $12.67 | $20.75 |
52-Week Low | $8.75 | $6.03 |
Typical Hold Time | 21 Days | 0 Days |
Enterprise Value | $9.72B | $2.93B |
Signals from Pluang's Aura AI — not financial advice
Liberty Global (LBTYK) trades at $8.41, down 5.72% on the day and near 52-week lows. The stock shows bearish technical signals with negative moving averages and oscillators, though RSI indicates oversold conditions. Fundamentally, the company reported a net loss of $7.14B in 2025 despite $4.88B revenue, but cash flow remains positive at $264.8M. Recent developments include the VodafoneZiggo acquisition and preparations for Ziggo Group's 2027 listing.
The outlook remains challenging with persistent losses and bearish technicals, but analyst consensus is bullish with a $12.67 price target. Key opportunities include Ziggo Group's planned spin-off and AI partnerships, while risks involve execution on profitability and competitive pressures in telecom markets.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →